<DOC>
	<DOCNO>NCT00237185</DOCNO>
	<brief_summary>In core study , participant unresectable metastatic gastrointestinal stromal tumor express c-kit treat either 400 mg 600 mg imatinib mesylate 3 year . The 10 year extension study allow participant , successfully complete core study , continue study treatment imatinib mesylate provide still benefit treatment demonstrate safety concern per investigator 's opinion .</brief_summary>
	<brief_title>A Study Efficacy Safety Imatinib Mesylate Patients With Unresectable Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Men nonpregnant woman ≥18 year age histopathologically document diagnosis malignant GIST unresectable and/or metastatic . Confirmation KIT ( CD117 ) expression via immunohistochemical analysis tumor sample also require At least one measurable lesion , define Southwestern Oncology Group ( SWOG ) Solid Tumor Response Criteria , previously embolized irradiated Performance status ≤3 define Eastern Cooperative Oncology Group ( ECOG ) criterion , well life expectancy ≥6 month adequate end organ function define follow : Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) , aspartate aminotransferase ( SGOT ) alanine aminotransferase ( SGPT ) &lt; 2.5 x ULN ( &lt; 5 x ULN hepatic metastasis present ) , creatinine &lt; 1.5 x ULN , absolute neutrophil count ( ANC ) &gt; 1.5 x 10^9/L , platelet count &gt; 100 x 10^9/L Patients few five year diseasefree survival ( nonGIST ) malignancy except malignancy currently clinically significant require active intervention malignancy basal cell skin cancer cervical carcinoma situ Patients know brain metastasis Evidence follow disorder : Grade III/IV cardiac failure define New York Heart Association Criteria , severe concomitant disease , acute know chronic liver disease ( i.e . chronic active hepatitis , cirrhosis ) HIV infection Chemotherapy investigational therapy within four week prior study entry ( six week nitrosourea mitomycinC ) and/or radiotherapy ≥25 % bone marrow Inability cooperate Major surgery within two week exposure investigational agent within 28 day entry study Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>GIST</keyword>
	<keyword>c-kit</keyword>
	<keyword>imatinib mesylate</keyword>
</DOC>